Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 29, 2025
Event: Exercise of an option by Roche under a Collaboration and License Agreement dated December 5, 2021.
Key Financial Metrics
Revenue Impact: The filing reports an immediate acceptance fee of $30 million payable by Roche to Recursion Pharmaceuticals.
Other Metrics: The filing text does not provide clear values for net profit, cash flow, operating margins, total debt, or liquidity positions.
Material Changes
This report details a specific contractual milestone rather than a period-over-period financial comparison. The material change is the activation of a payment obligation by Roche for the "Microglia Map," a whole genome map of the brain's immune cells generated by Recursion.
Outlook, Commentary, and Risks
Management Commentary: The Company announced the successful exercise of the option by Roche, validating the delivery of the Microglia Map asset.
Risks and Contingencies: The filing does not disclose new risks or contingencies beyond the standard execution of the existing agreement terms.
Investor Verification Checklist
- Confirm the timing of the $30 million cash receipt and its classification in the next quarterly financial report.
- Review the full terms of the December 5, 2021 Agreement to understand future milestone or royalty obligations.
- Verify the strategic significance of the "Microglia Map" asset for Recursion's broader drug discovery platform.